Effects of intracerebroventricular administration of 6-hydroxydopamine on ouabain-like immunoreactivity in plasma and the hypothalamo-pituitary axis in rats

Journal of Hypertension

Volumn 14, Issue 4, 1996, Pages 447-452

  Komiyama, Yutaka ^a   Mori, Tsuyoshi ^a   Okuda, Kazuhiro ^a   Munakata, Machiko ^a   Murakami, Takashi ^a   Masuda, Midori ^a   Goto, Atsuo ^a   Yamada, Kaoru ^a   Takahashi, Hakuo ^a,b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

6 hydroxydopamine; Hypertension; Hypothalamus; Noradrenaline; Ouabain; Pituitary

Indexed keywords

CATECHOLAMINE; NORADRENALIN; OUABAIN; OXIDOPAMINE;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOREACTIVITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; RAT; TISSUE LEVEL; VENOUS BLOOD;

EID: 0029954729     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199604000-00006     Document Type: Article

References (31)

1. Hamlyn JM, Blaustein MP, Bova S, Ducharme DW, Harris DW, Mandel F, et al.: Identification and characterization of an ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991, 88:6259-6263.
2. Mathews WR, Ducharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, et al.: Mass spectral characterization of an endogenous digitalislike factor from human plasma. Hypertension 1991, 17:930-935.
3. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, et al.: Development of an immunoassay for endogenous digitalislike factor. Hypertension 1991, 17:936-943.
4. Tymiak AA, Norman JA, Bolgar M, DiDonato GC, Lee H, Parker WL, et al.: Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci USA 1993, 90:8189-8193.
5. Takahashi H, Ihara N, Terano Y, Yamada H, Nishimura M, Nakanishi T, et al.: Ouabain-like immunoreactive substances exist in the hypothalamus and the adrenal medulla in rats. Pathophysiology 1994, 1:25-28.
6. Takahashi H, Okabayashi H, Matsuzawa M, Suga K, Ikegaki I, Yoshimura M, et al.: Evidence for an endogenous digitalis-like substance in the hypothalamo-pituitary axis in rats - implications in the hypertension associated with an excess intake of sodium. Jpn Circ J 1987, 21:439-446.
7. Takahashi H, Matsuzawa M, Suga K, Ikegaki I, Nishimura M, Yoshimura M, et al.: Hypothalamic digitalis-like substance is released with sodium-loading in rats. Am J Hypertens 1988, 1:146-151.
8. Yamada H, Ihara N, Takahashi H, Yoshimura M, Sano Y: Distribution of the endogenous digitalis-like substance (EDLS)-containing neurons labeled by digoxin antibody in hypothalamus and three circumventricular organs of dog and macaque. Brain Res 1992, 584:237-243.
9. Yamada H, Naruse M, Naruse K, Demura H, Takahashi H, Yoshimura M, et al.: Histological study on ouabain Immunoreactivities in the mammalian hypothalamus. Neurosci Lett 1992, 141:143-146.
10. Haupert GT, Carilli CT, Cantley LC: Hypothalamic sodium transport inhibitor is a high-affinity reversible inhibitor of Na-K ATPase. Am J Physiol 1984, 247:F919-F924.
11. Lichstein D, Samuelov S: Characterization of ouabain receptor in neuronal tissue: evidence for endogenous ouabain-like compound. Isr J Med Sci 1982, 18:45-50.
12. Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, Ferrari P: Ouabainlike factor in Milan hypertensive rats. Am J Physiol 1992, 263:F739-F748.
13. Huang BS, Leeren FHH: Brain 'ouabain' mediates the sympathoexcitatory and hypertensive effects of high sodium intake in Dahl salt sensitive rats. Circ Res 1994, 74:586-595.
14. Hokfelt T, Elde R, Fuxe K, Johansson O, Ljungdahl A, Goldstein M, et al.: Aminergic pathways in the nervous system with special reference to the hypothalamus. In The Hypothalamus. Edited by Reichlin RJ, Baldessarini RJ, Martin JB. New York: Raven Press; 1978:69-135.
15. Brody MJ, Fink GD, Buggy J, Haywood JR, Gordon FJ, Johnson AK: The role of the anteroventral third ventricle (AV3V) region in experimental hypertension. Circ Res 1978, 43 (suppl 1):2-14.
16. Ciriello J, Kline RL, Zhang TX, Gaverson MM: Paraventricular nucleus (PVH) lesions alter the development of spontaneous hypertension. Feds Proc 1983, 42:495-501.
17. Komiyama Y, Mori T, Murakami T, Masuda M, Takahashi H: Production of ouabain-like factors of hypothalamo-pituitary origin, determined by a sensitive ELISA for ouabain, is increased in DOCA-salt hypertensive rats. Pathophysiology 1995, 2:35-40.
18. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ: Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods 1989, 125:279-285.
19. Takahashi H, Bunag RD: Centrally-induced cardiovascular and sympathetic responses to bradykinin in rats. J Pharmacol Exp Ther 1981, 216:192-198.
20. Gowinski J, Iversen L: Regional studies of catecholamines in the rat brain. J Neurochem 1966, 13:655-662.
21. Yuan C, Manunta P, Hamlyn JM, Chen S, Bohen E, Haddy FJ, et al.: Long term ouabain administration produces hypertension in rats. Hypertension 1993, 22:178-187.
22. Dutta S, Marks BH: Distribution of ouabain and digoxin in the rat and guinea pig. Life Sci 1966, 5:915-920.
23. Gomez-Sanchez EP, Foecking MF, Sellers D, Blankenship MS, Gomes-Sanchez CE: Is the circulating ouabain-like compound ouabain? Am J Hypertens 1994, 7:647-650.
24. Lewis LK, Yandle TG, Lewis JG, Richards AM, Pidgeon GB, Kaaja RJ, et al.: Ouabain is not detectable in human plasma. Hypertension 1994, 24:549-555.
25. Takahashi H, Ueda S, Nishimura M, Ikegaki I, Nakanishi T, Sano Y, et al.: Reduced content of norepinephrine and dopamine in the area A2 of medulla oblongata in spontaneously hypertensive rats. Ther Res 1990, 11:3934-3929.
26. Uretsky NJ, Iversen LL: Effects of 6-hydroxydopamine on catecholamine containing neurons in the rat brain. J Neurochem 1970, 17:269-276.
27. Breese GR, Traylor TD: Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol 1971, 42:88-99.
28. Jandhyala BS, Lokhandwala MF, Kivlighn SD, Ansari AF, De Feo ML: Intracisternal administration of pergolide, a dopamine receptor agonist triggers the release of an inhibitor of ouabain-sensitive sodium, potassium-dependent adenosine triphosphate and enhances vascular reactivity in anaesthetized dogs. Clin Sci Colch 1987, 73:183-188.
29. Takahashi H, Terano Y: Ouabain-like immunoreactivity in the brain and the adrenal medulla is increased in DOCA-salt hypertensive rats. In The Sodium Pump. Edited by Bamberg E, Schoner W. New York: Springer; 1994:775-778.
30. +-pump activity. Hypertension 1982, 4:575-580.
31. Takahashi H, Matsusawa M, Nishimura M, Ikegaki I, Nakanishi T, Yoshimura M: Digoxin-like immunoreactivity increases with intravenous injections of saline in rats. Clin Exp Pharmacol Physiol 1991, 18:505-508.